The ancestry-specific and transethnic genome-wide meta-analysis summary statistics for association with HbA1c, and published data included in this study, are available to download from the MAGIC website, [www.magicinvestigators.org/downloads](http://www.magicinvestigators.org/downloads). Uniform analysis plan(s) showing the QC and data analysis steps in detail are provided in the supporting information file [S1 Analysis Plans](#pmed.1002383.s018){ref-type="supplementary-material"}.

Introduction {#sec007}
============

Type 2 diabetes (T2D) is a health scourge rising unabated worldwide, escaping all past and current control measures, in part because only half of prevalent T2D worldwide has been clinically diagnosed \[[@pmed.1002383.ref001]\]. Glycated hemoglobin (HbA1c) is an accepted diagnostic test for T2D and a principal clinical measure of glycemic control in individuals with diabetes. T2D arises from the environment interacting with genetics. Studies investigating genetic contributions to HbA1c in individuals of European \[[@pmed.1002383.ref002]--[@pmed.1002383.ref004]\] and Asian ancestry \[[@pmed.1002383.ref005]--[@pmed.1002383.ref007]\] have identified 18 loci influencing HbA1c through glycemic and nonglycemic pathways, the latter primarily reflecting erythrocytic biology. Alterations in HbA1c that are due to genetic variation acting through nonglycemic pathways may not accurately reflect ambient glycemia or T2D risk and could affect the validity of HbA1c as a diagnostic test and measure of glycemic control in some individuals or populations. Some genetic variants (e.g., the sickle cell variant HbS) that vary in frequency across ancestries can interfere with the accuracy of certain assays \[[@pmed.1002383.ref008]\]. Further, certain hematologic conditions associated with shortened erythrocyte lifespan (e.g., hemolytic anemias) lower HbA1c values irrespective of the assay performed. HbA1c values in such patients may no longer accurately reflect ambient glycemia \[[@pmed.1002383.ref009]\].

Epidemiologic studies have reported ethnic differences in HbA1c, with African Americans having, on average, higher HbA1c than European ancestry Americans \[[@pmed.1002383.ref010]\]. While these differences are largely due to demographic and metabolic factors \[[@pmed.1002383.ref011],[@pmed.1002383.ref012]\], genetic factors associated with hematologic conditions that impact erythrocyte turnover may confound the relationship between HbA1c and glycemia, causing misclassification of T2D diagnosis \[[@pmed.1002383.ref008],[@pmed.1002383.ref013]\].

This study had 3 aims, the first was to expand genetic discovery efforts to larger sample sizes, including populations of ancestries not previously studied, to uncover novel loci influencing HbA1c and that might capture a greater fraction of the variability in HbA1c. Second, as done in previous studies, we aimed to classify the variants as acting through glycemic or erythrocytic biology. Thirdly, as erythrocytic variants may influence HbA1c due to effects on the red blood cell (RBC), we wished to explore whether this might lead to HbA1c values that no longer reflected ambient glycemia. To do this, we specifically tested the hypothesis that HbA1c-associated genetic variants, particularly those that act through erythrocytic pathways, influence the performance of HbA1c for diabetes risk prediction and diabetes diagnoses ([S1 Fig](#pmed.1002383.s014){ref-type="supplementary-material"}).

Methods {#sec008}
=======

Analysis plans were followed and can be found in [S1 Analysis Plans](#pmed.1002383.s018){ref-type="supplementary-material"}.

Genetic discovery study participants {#sec009}
------------------------------------

In the genetic discovery analysis, we combined data from up to 159,940 participants (maximum number available for any variant) of European, African American, East Asian, and South Asian ancestry, including subsets from previous publications \[[@pmed.1002383.ref004],[@pmed.1002383.ref005]\] ([S1 Table](#pmed.1002383.s002){ref-type="supplementary-material"}, [S2 Fig](#pmed.1002383.s015){ref-type="supplementary-material"}). All participants were free of diabetes defined by physician diagnosis, medication use, or fasting glucose (FG) ≥ 7 mmol/L. A small number of cohorts also removed individuals with 2hr glucose (2hrGlu) ≥ 11.1 mmol/L, or HbA1c ≥ 6.5%, where FG was not available (details of exclusions by individual cohorts, [S1 Table](#pmed.1002383.s002){ref-type="supplementary-material"}). Analysis followed the details in [S1 Analysis Plans](#pmed.1002383.s018){ref-type="supplementary-material"} (Hemoglobin A1c Genetic Discovery Analysis Plan).

HbA1c measurement {#sec010}
-----------------

Where possible, studies reported HbA1c as a National Glycohemoglobin Standardization Program (NGSP) percent \[[@pmed.1002383.ref014]\] ([S1 Table](#pmed.1002383.s002){ref-type="supplementary-material"}).

Genotyping and quality control {#sec011}
------------------------------

Each cohort was genotyped on commercially available genome-wide arrays (for instance, the Affymetrix Genome-Wide Human SNP Assay 6.0 or the Illumina Human610-Quad BeadChip) or the Illumina CardioMetabochip (Metabochip) \[[@pmed.1002383.ref015]\]. Variant and sample quality control (QC) was conducted within each cohort following a shared analysis plan ([S1 Analysis Plans](#pmed.1002383.s018){ref-type="supplementary-material"}). Cohorts were advised to keep SNPs with hardy-weinberg-disequilibrium *p*-value ≥ 1 × 10^−6^, SNP genotyping call rate ≥ 95% and minor allele frequency (MAF) ≥ 1% (full details of SNP and sample QC can be found in [S1 Table](#pmed.1002383.s002){ref-type="supplementary-material"}). Following QC, studies with genome-wide array data were imputed (primarily using the Phase 2 of the International HapMap Project reference panel \[[@pmed.1002383.ref016]\], see [S1 Table](#pmed.1002383.s002){ref-type="supplementary-material"}, row 40), and poorly imputed variants (variants which could not reliably be inferred from surrounding variants) were excluded based on standard imputation quality thresholds (R-sq \< 0.3, INFO \< 0.4). Approximately 2.5 million SNPs were available for analysis after imputation and QC ([S1 Table](#pmed.1002383.s002){ref-type="supplementary-material"}). QC of the Metabochip data is described elsewhere, but included filtering out poorly genotyped individuals or low-quality SNPs \[[@pmed.1002383.ref017]\]. Variant association testing in men and women combined was conducted under an additive model adjusting for study-specific covariates and was limited to variants with MAF of at least 1% in each cohort. Details of the study cohorts, genotyping platforms and QC criteria, imputation reference panel, covariates in the analysis, and software used are provided for each study in [S1 Table](#pmed.1002383.s002){ref-type="supplementary-material"}. Our study followed STREGA guidelines ([S1 Checklist](#pmed.1002383.s001){ref-type="supplementary-material"}).

Genetic discovery using ancestry-specific and trans-ancestry meta-analyses {#sec012}
--------------------------------------------------------------------------

Association data were combined within each ancestry group using a fixed-effects meta-analysis in METAL, which assumes the SNP effect is the same for each study within an ancestry \[[@pmed.1002383.ref018]\]. Results for each cohort were corrected for any systematic biases, such as residual population structure using the genomic control inflation factor, λ~GC~ \[[@pmed.1002383.ref017],[@pmed.1002383.ref019]\]. We excluded variants from further follow-up if they had an ancestry-specific sample size *N* \< 20,000 in Europeans, *N* \< 3,000 in African Americans, *N* \< 7,000 in East Asians, and *N* \< 3,000 in South Asians (minimum number of samples, where the threshold was chosen to minimize signals driven by a single cohort), or evidence of significant within-ancestry heterogeneity, suggesting effect size significantly differs between cohorts of the same ancestry (Cochran's Q-test heterogeneity *p*-value \< 0.0001). We retained the lead variant in the X-chromosome analysis of the African American ancestry data (rs1050828, G202A in *G6PD*) despite significant heterogeneity, as it was a strong biological candidate.

Ancestry-specific meta-analysis results were conservatively corrected for a second round of genomic control by ancestry: European (λ~GC~ = 1.072); African American (λ~GC~ = 1.020); East Asian (λ~GC~ = 1.027); South Asian (λ~GC~ = 1.004); and combined using the Meta-Analysis of Transethnic Association (MANTRA) software that accounts for allelic heterogeneity across ancestry groups \[[@pmed.1002383.ref020]\].

Identification of primary and secondary distinct HbA1c-associated signals {#sec013}
-------------------------------------------------------------------------

Variants were considered to be significantly associated with HbA1c when they met standard genome-wide significant thresholds (based on *p* = 0.05 divided by the estimated number of independent tests across the genome), of *p* \< 5 × 10^−8^ in the European and Asian, or *p* \< 2.5 × 10^−8^ in African American \[[@pmed.1002383.ref021]\] ancestry-specific meta-analyses, or a log~10~ Bayes Factor ≥6 in the transancestry meta-analysis. All significant variants within 500 kb of a lead (most significantly associated) variant were grouped into a single locus. Novel loci were by definition \>500 kb from previously reported HbA1c-associated variants. We ran approximate conditional analyses using the Genome-wide Complex Trait Analysis (GCTA) software \[[@pmed.1002383.ref022],[@pmed.1002383.ref023]\] (following analysis plans detailed in [S1 Analysis Plans](#pmed.1002383.s018){ref-type="supplementary-material"}, Conditional analyses in GCTA) using the Women's Genome Health Study (WGHS, Europeans), Jackson Heart Study (JHS, African Americans), Singapore Malay Eye Study (SiMES, East Asians), and the London Life Sciences Prospective Population Study (LOLIPOP, South Asians) as reference populations for linkage disequilibrium (LD) estimates, to confirm the lead variants on the autosomes (within 1 Mb) were distinct, and similarly used exact conditional regression for the African-American signals on the X-chromosome in JHS.

To identify distinct signals at associated loci (that is, secondary signals), we performed approximate conditional analyses using GCTA, conditioning on lead variants identified in the transancestry MANTRA analysis. Where the lead variant was absent in a cohort, an exact proxy (r^2^ = 1) was used, unless the variant was very low frequency or monomorphic.

Classification of variants as glycemic or erythrocytic {#sec014}
------------------------------------------------------

We extracted summary association statistics from publicly available meta-analysis results for glycemic \[[@pmed.1002383.ref017],[@pmed.1002383.ref024]--[@pmed.1002383.ref026]\] and blood-cell \[[@pmed.1002383.ref027]\] traits and asked a subset of the genome-wide discovery cohorts to repeat association analyses for each lead variant, conditioning on any one of FG, 2hrGlu, hemoglobin level (Hb), mean corpuscular volume (MCV), or mean corpuscular hemoglobin (MCH), where available ([S3 Fig](#pmed.1002383.s016){ref-type="supplementary-material"}, [S2 Table](#pmed.1002383.s003){ref-type="supplementary-material"} and [S3 Table](#pmed.1002383.s004){ref-type="supplementary-material"}).

Variants were classified as "glycemic" if they were associated (*p* \< 0.0001) with any of the glycemic traits from publicly available results or had ≥25% attenuation of variant HbA1c effect size in association models conditioned on fasting or 2hrGlu. That is, evidence of being associated with any of the glycemic traits or a reduction in the effect of the variant on HbA1c after repeated association analysis in a model additionally adjusting for fasting/2hrGlu, suggested the observed association with HbA1c was being driven through an association with fasting/2hrGlu. Variants not classified as glycemic were classified as "erythrocytic" if they were associated (*p* \< 0.0001) with Hb, MCH, MCV, PCV, RBC, or MCHC in the publicly available results or, as above, had ≥25% attenuation of effect size in Hb-, MCV-, or MCH-conditioned models (suggesting the observed association with HbA1c was being driven through an association with these blood cell traits). The 25% attenuation threshold was chosen as the optimal balance between specificity and sensitivity based on comparisons with the classification based only on association with any of the glycemic/erythrocytic traits. Two SNPs were classified based on evidence from the literature, rs12132919 (*TMEM79*) was classified as erythrocytic based on association with MCHC in Japanese individuals \[[@pmed.1002383.ref028]\] and rs7616006 (*SYN2*) was classified as erythrocytic based on association with platelet count in Europeans \[[@pmed.1002383.ref029]\].

Variants associated with HbA1c but not glycemic or erythrocytic traits remained "unclassified" ([S3 Fig](#pmed.1002383.s016){ref-type="supplementary-material"}). A single variant (rs579459 near *ABO*) was classified as both glycemic and erythrocytic, but as we were primarily concerned about variants that might affect HbA1c without reflecting ambient glycemia and this variant also affected glycemia, we treated it as glycemic in all analyses.

Effect of HbA1c genetic scores on reclassification of prevalent undiagnosed T2D for population screening using HbA1c {#sec015}
--------------------------------------------------------------------------------------------------------------------

Analyses on the reclassification of prevalent T2D around the HbA1c 6.5% threshold before and after accounting for the contribution of erythrocytic variants were conducted in up to 19,380 individuals and incident T2D prediction analyses in up to 33,241 individuals from European, African, and East Asian ancestry cohorts (derived in part from discovery cohorts; in [S4 Table](#pmed.1002383.s005){ref-type="supplementary-material"}, and following the details in the [S1 Analysis Plans](#pmed.1002383.s018){ref-type="supplementary-material"}, Net-reclassification analysis). We acknowledge that nonindependent GWAS discovery and application cohorts can lead to inflated effect estimates \[[@pmed.1002383.ref030]\]; however, this was not evident in our study, and effect estimates across all cohorts were similar with low heterogeneity.

We estimated reclassification of prevalent T2D status by HbA1c after accounting for the contribution of erythrocytic loci in 5 population-based cohorts with 3 ancestries partially overlapping with the discovery GWAS: the Framingham Heart Study (FHS), the Atherosclerosis Risk in Communities Study (ARIC), and the Multiethnic Study of Atherosclerosis (MESA) in individuals of European ancestry; ARIC and MESA in African Americans; and MESA, the Taiwan-Metabochip Study for Cardiovascular Disease (TAICHI), and the Singapore Prospective Study (SP2) in East Asians (*N* = 19,380). Variant-adjusted HbA1c was calculated as: $$Y_{i} - {\sum{{\hat{\beta}}_{k}\left( {g_{ki} - E\left( g_{ki} \right)} \right)}}$$ where *Y*~*i*~ was the measured HbA1c for individual, i, ${\hat{\beta}}_{i}$ is the ancestry-specific, meta-analytic *β* coefficient for the k^th^ erythrocytic SNP, *g*~*ki*~ is the dosage (estimated number of HbA1c-raising alleles), and E(*g*~*ki*~) was two times the HbA1c-raising allele frequency. When the less frequent (minor) allele was associated with higher HbA1c, it was coded as the HbA1c-raising allele, when it was associated with lower HbA1c, the more frequent (major) allele was coded as the HbA1c-raising allele. As some HbA1c-raising alleles in one ancestry could be HbA1c-lowering in a different ancestry, we coded HbA1c-raising alleles by ancestry.

Participants on antidiabetic therapy were excluded, and screen-detected T2D was defined as FG ≥ 7 mmol/L. For the reclassification analysis, we constructed 2-by-2 tables showing the proportion of participants reclassified around the HbA1c 6.5% diagnostic threshold, with and without adjusting measured HbA1c for the contribution of erythrocytic loci.

### Calculation of genetic risk scores {#sec016}

Genetic risk scores of erythrocytic variants and glycemic variants (GS-E and GS-G, respectively) were calculated as detailed in [S1 Analysis Plans](#pmed.1002383.s018){ref-type="supplementary-material"} (Investigate the Effect of Glycemic and Erythrocytic Hemoglobin A1c (HbA1c) Genetic Variants on Diabetes Prediction), as standard in the field, by summing the number of ancestry-specific HbA1c-raising alleles at each variant (0, 1, 2, or expected number of alleles based on the probability of each genotype), multiplied by their ancestry-specific β coefficients for HbA1c from the genome-wide association study (GWAS) meta-analysis multiplied by the number of variants and divided by the sum of β coefficients \[[@pmed.1002383.ref031]\]. This means the contribution of each associated variant to the trait, in a given individual, is influenced by the number of "risk alleles" (or in this case HbA1c-raising alleles) and the effect of the variant on the trait (increase in HbA1c estimated from the meta-analysis).

Effect of HbA1c genetic scores on prediction of incident T2D {#sec017}
------------------------------------------------------------

We tested the hypothesis that glycemic and erythrocytic HbA1c loci predicted incident T2D differently in Europeans, East Asians, and African Americans from 5 cohorts (partially overlapping with the discovery GWAS) with prospective follow-up: FHS, the European Prospective Investigation into Cancer and Nutrition InterAct project (EPIC-InterAct), ARIC, MESA, and the Singapore Chinese Health Study (SCHS) (*N* = 33,241). Using age- and sex-adjusted regression models, we tested the association between the genetic scores GS-E or GS-G and incident T2D, defined by FG ≥ 7 mmol/L, 2hrGlu ≥ 11.1 mmol/L, antidiabetic medication use, or a physician diagnosis for T2D, accrued over a 10-to-15-year follow-up period. Clinical practice guidelines did not include HbA1c as a diagnostic test until 2010. As the majority of incident T2D cases were accrued before 2010, participants are very unlikely to have received a T2D diagnosis based only on HbA1c measurements. To test whether individuals with higher GS-E, compared to those with lower GS-E, had lower T2D risk for the same HbA1c, we adjusted models for baseline HbA1c. We meta-analyzed results using a fixed-effects meta-analysis and assessed heterogeneity using Higgin\'s I-squared. See [S1 Analysis Plans](#pmed.1002383.s018){ref-type="supplementary-material"} (Investigate the Effect of Glycemic and Erythrocytic Hemoglobin A1c (HbA1c) Genetic Variants on Diabetes Prediction) for analysis plan.

Ancestral differences in the genetic architecture of HbA1c {#sec018}
----------------------------------------------------------

In FHS, ARIC, MESA, and SCHS, we calculated the difference in HbA1c of individuals at the bottom and top 5% of the distribution of an ancestry-specific GS composed of all 60 variants (GS-Total) and an equivalent analysis using GS-E.

We also pursued additional analyses at chromosome X rs1050828 because this single variant showed the largest effect on HbA1c in African Americans and was monomorphic in the other ancestries. The T allele is known to be associated with glucose-6-phosphate dehydrogenase (G6PD) deficiency, an enzymatic defect causing hemolytic anemia \[[@pmed.1002383.ref032],[@pmed.1002383.ref033]\]. Imperfect correlation between HbA1c and glycemia may indicate the impact of reduced erythrocyte lifespan on HbA1c in individuals with the T allele. Fructosamine, a measure of serum protein glycation not influenced by erythrocyte-related factors, reflects average glycemia over the previous 2--3 weeks. Following the analysis plan detailed in [S1 Analysis Plans](#pmed.1002383.s018){ref-type="supplementary-material"} (The Difference Between Fructosamine-inferred HbA1c and Measured HbA1c) we thus calculated the estimated residuals from a linear regression of HbA1c on fructosamine in ARIC African Americans (*N* = 1,676) to determine whether the T allele was associated with lower HbA1c than predicted by fructosamine, suggesting that the T allele artificially lowered HbA1c through a reduction in the average erythrocytic lifespan. We then reported the mean estimated residuals by genotype (women: CC, CT, TT; men: C, T).

### Estimated number of African Americans with T2D in the United States whose diagnosis would be missed due to the *G6PD* variant if screened with HbA1c {#sec019}

Using publicly-available data from the National Health and Nutrition Examination Survey (NHANES) 2013--2014 \[[@pmed.1002383.ref034]\], a nationally representative sample of US residents, we calculated the proportion of African American adults (aged ≥ 18 years) with T2D who would be missed by not accounting for rs1050828 when using a single HbA1c diagnostic threshold of 6.5%, assuming the observed effect size of rs1050828, allele frequency of 11% and accounting for NHANES sampling design. The study sample was restricted to 1,133 adults, aged ≥ 18 years, who self-identified as non-Hispanic black with measured HbA1c in 2013--2014. We defined known T2D by self-reported physician diagnosis or medication use. Assuming Hardy-Weinberg Equilibrium and a T allele frequency of 11% for the *G6PD* variant in our sample, we lowered the diagnostic threshold from the widely accepted 6.5%-units cut-point to 5.7%-units in men with the T genotype, 5.8%-units in women with the TT genotype, and 6.2%-units in women with the CT genotype. We then calculated the proportion of African American individuals with missed T2D diagnosis if screened with HbA1c using the 6.5% diagnostic threshold. We applied procedures to account for sampling probabilities and complex sampling design to enable population-level inferences. Data analysis was performed using SAS (version 9.2 or 9.3; SAS Institute, Cary, NC).

Results {#sec020}
=======

HbA1c-associated genetic variants and classification into glycemic and nonglycemic pathways {#sec021}
-------------------------------------------------------------------------------------------

To discover new genetic loci influencing HbA1c in populations from 4 different ancestries (European, African American, East Asian, and South Asian), we performed within-ancestry fixed-effects genome-wide association meta-analyses and transancestry meta-analyses using a model that allowed for different effects between ancestry groups (Methods, [S2 Fig](#pmed.1002383.s015){ref-type="supplementary-material"}). Using this approach in up to 159,940 participants without diabetes, we identified 60 variants associated with HbA1c at genome-wide significance ([Fig 1](#pmed.1002383.g001){ref-type="fig"}, [Table 1](#pmed.1002383.t001){ref-type="table"} and [S5 Table](#pmed.1002383.s006){ref-type="supplementary-material"}). Of 60, 18 have been previously reported, and 42 were novel, including distinct secondary signals at 5 known loci. To classify the associated loci into groups reflecting their likely mode of action on HbA1c, we repeated association analyses conditioning on erythrocytic or glycemic traits and performed lookups in publicly-available association results summary statistics for additional glycemic and erythrocytic traits (Methods, [S3 Fig](#pmed.1002383.s016){ref-type="supplementary-material"}, [S2 Table](#pmed.1002383.s003){ref-type="supplementary-material"} and [S3 Table](#pmed.1002383.s004){ref-type="supplementary-material"}). Based on the combined results from conditional and lookup results, we were able to classify 22 variants as erythrocytic and 19 as glycemic, with 19 remaining unclassified ([Fig 1](#pmed.1002383.g001){ref-type="fig"}, [Table 1](#pmed.1002383.t001){ref-type="table"} and [S5 Table](#pmed.1002383.s006){ref-type="supplementary-material"}).

![Manhattan plot of HbA1c associated variants.\
Manhattan plot of the transethnic meta-analysis results in MANTRA. The dashed grey line indicates log~10~BF = 6. Grey and green points denote known/novel loci, respectively. The lead HbA1c-associated variants identified through the ancestry-specific/transethnic analyses are circled in purple (the *G6PD* variant was not included in the MANTRA analysis, but the locus on the X-chromosome is indicated in the figure). Lines joining the plot & SNP number denote known loci (black), novel loci (green), and loci with a secondary distinct signal (red). MANTRA, Meta-Analysis of Transethnic Association.](pmed.1002383.g001){#pmed.1002383.g001}
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###### Table of HbA1c associated variants.

Table with results and classification of the 60 HbA1c-associated variants. SNP number corresponds to number in [Fig 1](#pmed.1002383.g001){ref-type="fig"}.
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  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  SNP   Markername       Chr.   Position (bp)   Effect Allele   Other Allele   Gene       Status   Signals    Classification     European ancestry\                        Trans-ethnic MANTRA log10BF
                                                                                                                                 METAL\                                    
                                                                                                                                 *p*-value                                 
  ----- ---------------- ------ --------------- --------------- -------------- ---------- -------- ---------- ------------------ ----------------------------------------- -----------------------------
  1     **rs2375278**    1      25401625        A               G              SYF2       Novel    Single     Unclassified       2.03 × 10^−7^                             6.93

  2     **rs267738**     1      149207249       T               G              CERS2      Novel    Single     Unclassified       2.59 × 10^−9^                             6.41

  3     **rs12132919**   1      154584765       A               C              TMEM79     Known    Single     **Erythrocytic**   0.0169                                    10.08

  4     **rs857691**     1      156893002       T               C              SPTA1      Known    Single     **Erythrocytic**   3.97 × 10^−25^                            25.52

  5     **rs17509001**   2      23874735        C               T              ATAD2B     Novel    Single     Unclassified       1.94 × 10^−15^                            13.30

  6     **rs12621844**   2      48268239        T               C              FOXN2      Novel    Single     Unclassified       1.87 × 10^−8^                             5.32

  7     **rs13387347**   2      169463092       T               C              G6PC2      Novel    Multiple   **Glycemic**       0.308                                     5.77

  8     **rs560887**     2      169471394       C               T              G6PC2      Known    Multiple   **Glycemic**       1.48 × 10^−58^                            55.77

  9     **rs17256082**   2      175000610       C               T              SCRN3      Novel    Single     Unclassified       0.00112                                   6.27

  10    **rs7616006**    3      12242648        A               G              SYN2       Novel    Single     **Erythrocytic**   5.07 × 10^−10^                            10.16

  11    **rs9818758**    3      49357929        A               G              USP4       Novel    Single     Unclassified       7.74 × 10^−10^                            7.20

  12    **rs11708067**   3      124548468       A               G              ADCY5      Novel    Single     **Glycemic**       1.42 × 10^−12^                            10.62

  13    **rs8192675**    3      172207577       T               C              SLC2A2     Novel    Single     **Glycemic**       1.38 × 10^−11^                            10.33

  14    **rs4894799**    3      173278234       A               G              FNDC3B     Novel    Single     Unclassified       1.80 × 10^−6^                             6.05

  15    **rs13134327**   4      144879245       A               G              FREM3      Novel    Single     **Glycemic**       2.64 × 10^−15^                            12.66

  16    **rs11954649**   5      156988069       G               C              SOX30      Novel    Single     Unclassified       NA                                        6.20

  17    **rs7756992**    6      20787688        G               A              CDKAL1     Known    Single     **Glycemic**       2.80 × 10^−12^                            16.53

  18    **rs1800562**    6      26201120        G               A              HFE        Known    Multiple   **Erythrocytic**   4.67 × 10^−28^                            26.81

  19    **rs198846**     6      26215442        G               A              HFE        Novel    Multiple   **Erythrocytic**   1.18 × 10^−23^                            23.72

  20    **rs11964178**   6      109668728       A               G              C6orf183   Novel    Single     **Erythrocytic**   6.38 × 10^−10^                            7.03

  21    **rs11154792**   6      135473333       T               C              MYB        Known    Single     **Erythrocytic**   7.45 × 10^−18^                            17.89

  22    **rs592423**     6      139882386       A               C              CITED2     Novel    Single     **Erythrocytic**   3.96 × 10^−8^                             4.50

  23    **rs2191349**    7      15030834        T               G              DGKB       Novel    Single     **Glycemic**       2.09 × 10^−7^                             6.63

  24    **rs4607517**    7      44202193        A               G              GCK        Known    Multiple   **Glycemic**       8.76 × 10^−38^                            51.28

  25    **rs3824065**    7      44213783        C               T              GCK        Novel    Multiple   **Glycemic**       4.22 × 10^−35^                            31.87

  26    **rs6474359**    8      41668351        T               C              ANK1       Known    Multiple   Unclassified       1.50 × 10^−16^                            14.88

  27    **rs4737009**    8      41749562        A               G              ANK1       Known    Multiple   **Erythrocytic**   4.48 × 10^−27^                            32.08

  28    **rs6980507**    8      42502241        A               G              SLC20A2    Novel    Single     **Erythrocytic**   3.58 × 10^−8^                             8.73

  29    **rs11558471**   8      118254914       A               G              SLC30A8    Known    Single     **Glycemic**       1.38 × 10^−19^                            23.26

  30    **rs2383208**    9      22122076        A               G              MTAP       Novel    Single     **Glycemic**       7.04 × 10^−12^                            11.74

  31    **rs7040409**    9      90693056        C               G              C9orf47    Novel    Single     **Erythrocytic**   2.56 × 10^−14^                            11.29

  32    **rs1467311**    9      109576753       G               A              KLF4       Novel    Single     Unclassified       2.09 × 10^−7^                             8.72

  33    **rs579459**     9      135143989       C               T              ABO        Novel    Single     **Glycemic**       9.42 × 10^−9^                             10.14

  34    **rs4745982**    10     70759849        T               G              HK1        Known    Multiple   **Erythrocytic**   2.87 × 10^−65^                            63.05

  35    **rs10823343**   10     70761019        A               G              HK1        Novel    Multiple   Unclassified       1.68 × 10^−55^                            49.45

  36    **rs17747324**   10     114742493       C               T              TCF7L2     Known    Single     **Glycemic**       6.12 × 10^−11^                            8.49

  37    **rs3782123**    11     195198          C               A              BET1L      Novel    Single     Unclassified       1.51 × 10^−10^                            9.51

  38    **rs2237896**    11     2815016         G               A              KCNQ1      Novel    Single     **Glycemic**       0.00246                                   6.07

  39    **rs174577**     11     61361390        C               A              FADS2      Novel    Single     **Glycemic**       5.45 × 10^−7^                             8.45

  40    **rs11603334**   11     72110633        G               A              ARAP1      Novel    Single     **Glycemic**       6.85 × 10^−9^                             6.53

  41    **rs10830963**   11     92348358        G               C              MTNR1B     Known    Single     **Glycemic**       2.23 × 10^−23^                            26.64

  42    **rs11224302**   11     99961814        C               T              CNTN5      Novel    Single     **Erythrocytic**   4.76 × 10^−7^                             6.40

  43    **rs2110073**    12     6946143         T               C              PHB2       Novel    Single     Unclassified       4.44 × 10^−8^                             7.18

  44    **rs2408955**    12     46785398        T               G              SENP1      Novel    Single     **Erythrocytic**   1.42 × 10^−15^                            11.65

  45    **rs10774625**   12     110394602       G               A              ATXN2      Novel    Single     **Erythrocytic**   1.46 × 10^−8^                             6.38

  46    **rs11619319**   13     27385599        G               A              PDX1       Novel    Single     **Glycemic**       4.58 × 10^−7^                             8.38

  47    **rs576674**     13     32452302        G               A              KL         Novel    Single     **Glycemic**       1.39 × 10^−5^                             6.38

  48    **rs282587**     13     112399663       G               A              ATP11A     Known    Single     Unclassified       1.70 × 10^−12^                            13.92

  49    **rs9604573**    13     113571085       T               C              GAS6       Novel    Single     Unclassified       9.60 × 10^−9^                             6.72

  50    **rs11248914**   16     233563          T               C              ITFG3      Novel    Single     **Erythrocytic**   2.56 × 10^−14^                            10.60

  51    **rs1558902**    16     52361075        A               T              FTO        Novel    Single     Unclassified       3.27 × 10^−8^                             6.88

  52    **rs4783565**    16     67307691        A               G              CDH3       Novel    Single     **Erythrocytic**   1.73 × 10^−7^                             6.73

  53    **rs837763**     16     87381230        T               C              CDT1       Known    Single     **Erythrocytic**   1.68 × 10^−28^                            28.89

  54    **rs9914988**    17     24207230        A               G              ERAL1      Novel    Single     **Erythrocytic**   2.77 × 10^−11^                            11.34

  55    **rs2073285**    17     73628956        C               T              TMC6       Novel    Single     Unclassified       1.27 × 10^−4^                             6.47

  56    **rs1046896**    17     78278822        T               C              FN3KRP     Known    Single     Unclassified       4.46 × 10^−64^                            71.79

  57    **rs11086054**   19     17107737        A               T              MYO9B      Novel    Multiple   Unclassified       8.16 × 10^−6^                             9.12

  58    **rs17533903**   19     17117523        A               G              MYO9B      Known    Multiple   **Erythrocytic**   5.27 × 10^−12^                            9.912

  59    **rs4820268**    22     35799537        G               A              TMPRSS6    Known    Single     **Erythrocytic**   1.40 × 10^−22^                            20.79

  60    **rs1050828**    X      153417411       T               C              G6PD       Novel    Single     **Erythrocytic**   NA[\*](#t001fn001){ref-type="table-fn"}   NA
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

\*African American meta-analysis *p*-value for the *G6PD* variant (rs1050828) = 8.23 × 10^−135^. Chr, chromosome; MANTRA, Meta-Analysis of Transethnic Association

Effect of HbA1c genetic scores on reclassification of prevalent undiagnosed T2D in population screening using HbA1c {#sec022}
-------------------------------------------------------------------------------------------------------------------

Next, we tested whether erythrocytic variants influenced the ability of HbA1c to accurately classify individuals with diabetes when screening populations using a single HbA1c measurement. In 5 cohorts, among the 767 individuals with undiagnosed T2D by FG ≥ 7 mmol/L, 390 (50.8%) had measured HbA1c \< 6.5% and would remain undiagnosed based on HbA1c. After accounting for the effect of erythrocytic variants, 5 (1.3%) of these individuals were correctly reclassified to having a HbA1c ≥ 6.5%. Among the 18,613 individuals without T2D by FG \< 7 mmol/L, 266 (0.3%) had measured HbA1c ≥ 6.5% and would be incorrectly diagnosed with T2D by HbA1c. After accounting for the effect of erythrocytic variants, 50 (18.8%) of these individuals \[13 of 80 (16.3%) European ancestry, 28 of 109 (25.7%) African ancestry, 9 of 77 (11.7%) Asian ancestry\] were correctly reclassified to having a HbA1c\<6.5% ([Table 2](#pmed.1002383.t002){ref-type="table"}, [S6 Table](#pmed.1002383.s007){ref-type="supplementary-material"}). While adjusting for the effect of erythrocytic variants improved reclassification for individuals diagnosed with T2D by only HbA1c and not FG, it caused wrong reclassification for individuals diagnosed with T2D by both FG and HbA1c ([S6 Table](#pmed.1002383.s007){ref-type="supplementary-material"}), suggesting that accounting for the contribution of erythrocytic variants may not be relevant for individuals who already meet diagnostic thresholds using both FG and HbA1c.

10.1371/journal.pmed.1002383.t002

###### Reclassification of individuals with discordant T2D status based on prevailing diagnostic thresholds for FG and HbA1c before and after accounting for the effect of erythrocytic variants.

![](pmed.1002383.t002){#pmed.1002383.t002g}

                 FG ≥ 7 mmol/L but HbA1c \< 6.5% (*N* = 390)   FG \< 7mmol/L but HbA1c ≥ 6.5% (*N* = 266)         
  -------------- --------------------------------------------- -------------------------------------------- ----- ------------
  **European**   314                                           1 (0.3%)                                     67    13 (16.3%)
  **African**    64                                            4 (6.3%)                                     81    28 (25.7%)
  **Asian**      7                                             0 (0.0%)                                     68    9 (11.7%)
  **Total**      385                                           5 (1.3%)                                     216   50 (18.8%)

FG, fasting glucose; HbA1c, glycated hemoglobin

Effect of HbA1c genetic scores on prediction of incident T2D {#sec023}
------------------------------------------------------------

Next, we tested whether erythrocytic variants influenced the ability of HbA1c to predict incident diabetes in initially nondiabetic populations. GS-G was associated with increased incidence of T2D (odds ratio \[OR\] per weighted allele 1.05, 95% CI 1.04--1.06 *p* = 2.5 × 10^−29^) overall, although not in African Americans ([Fig 2](#pmed.1002383.g002){ref-type="fig"}, [S7 Table](#pmed.1002383.s008){ref-type="supplementary-material"}). GS-E was not associated overall with incident T2D (OR 1.00 95% CI 0.99--1.01, *p* = 0.60) ([Fig 3](#pmed.1002383.g003){ref-type="fig"}, [S7 Table](#pmed.1002383.s008){ref-type="supplementary-material"}), but was negatively associated with incident T2D in Europeans and African Americans after adjusting for HbA1c (OR 0.95, 95% CI, 0.94--0.96, *p* = 3.3 × 10^−16^) ([Fig 4](#pmed.1002383.g004){ref-type="fig"}, [S4 Fig](#pmed.1002383.s017){ref-type="supplementary-material"} and [S7 Table](#pmed.1002383.s008){ref-type="supplementary-material"}), meaning individuals with a higher GS-E will have a lower risk of developing T2D given the same HbA1c value, suggesting that despite having the same HbA1c value, this does not reflect the same level of glycemia.

![T2D prediction, glycemic genetic score.\
Forest plot of association between glycemic genetic score with incident T2D over a decade-long follow-up period, by ancestry. MESA (European and Asian ancestry) and the *G6PD* variant (rs1050828) in ARIC (European and African American) were not included in the discovery GWAS analysis. Effect estimates were combined in a fixed effects meta-analysis. Overall effect estimate: 1.05, 95% CI 1.04--1.06, *p* = 2.5 × 10^−29^. ARIC, Atherosclerosis Risk in Communities Study; ES, Effect Size; FHS, Framingham Heart Study; GWAS, genome-wide association study; G6PD, glucose-6-phosphate dehydrogenase; I-Squared, Higgin\'s I-squared statistic, a measure of heterogeneity; MESA, Multiethnic Study of Atherosclerosis; SCHS, Singapore Chinese Health Study; T2D, type 2 diabetes.](pmed.1002383.g002){#pmed.1002383.g002}

![T2D prediction, erythrocytic genetic score.\
Forest plot of association between erythrocytic genetic score with incident T2D over a decade-long follow-up period, by ancestry. MESA (European and Asian ancestry) and the *G6PD* variant (rs1050828) in ARIC (European and African American) were not included in the discovery GWAS analysis. Effect estimates were combined in a fixed effects meta-analysis. Overall effect estimate: 1.00, 95% CI 0.99--1.01, *p* = 0.60. ARIC, Atherosclerosis Risk in Communities Study; ES, Effect Size, FHS, Framingham Heart Study; GWAS, genome-wide association study; G6PD, glucose-6-phosphate dehydrogenase; I-Squared, Higgin\'s I-squared statistic, a measure of heterogeneity; MESA, Multiethnic Study of Atherosclerosis; SCHS, Singapore Chinese Health Study; T2D, type 2 diabetes.](pmed.1002383.g003){#pmed.1002383.g003}

![T2D prediction, erythrocytic genetic score adjusted for HbA1c as a binary variable.\
Forest plot of association between erythrocytic genetic score with incident T2D over a decade-long follow-up period adjusted for HbA1c as a binary variable (≥5.7% versus \<5.7%), by ancestry. HbA1c at baseline was not available in SCHS and was excluded from the meta-analysis. MESA (European and Asian ancestry) and the *G6PD* variant (rs1050828) in ARIC (European and African American) were not included in the discovery GWAS analysis. Effect estimates were combined in a fixed effects meta-analysis. Overall effect estimate: 0.95, 95% CI 0.94--0.96, *p* = 3.3 × 10^−16^. ARIC, Atherosclerosis Risk in Communities Study; ES, Effect Size; GWAS, genome-wide association study; FHS, Framingham Heart Study; G6PD, glucose-6-phosphate dehydrogenase; HbA1c, glycated hemoglobin; I-Squared, Higgin\'s I-squared statistic, a measure of heterogeneity; MESA, multiethnic study of atherosclerosis; SCHS, Singapore Chinese Health Study; T2D, type 2 diabetes.](pmed.1002383.g004){#pmed.1002383.g004}

Ancestral differences in the genetic architecture of HbA1c {#sec024}
----------------------------------------------------------

The population genetic history of African ancestry groups has undergone selective pressure due to the effects of malaria and other infectious diseases on erythrocytes, unlike in most European ancestry populations \[[@pmed.1002383.ref035]\]. This led us to seek ancestral differences in the genetic determinants of HbA1c. The variance in HbA1c levels explained by all 60 genetic variants over a basic regression model including age and sex was 4.2%--5.8% in Europeans, 6.0%--14.3% in East Asians, and 8.9%--9.7% in African Americans ([S8 Table](#pmed.1002383.s009){ref-type="supplementary-material"}). In addition, compared to Europeans and East Asians, African Americans had the largest difference in mean HbA1c between the bottom and top 5% of the GS-Total distribution (0.91%-units, 95% CI 0.78--1.05; [Fig 5](#pmed.1002383.g005){ref-type="fig"} and [S9 Table](#pmed.1002383.s010){ref-type="supplementary-material"}).

![Mean HbA1c of individuals at the bottom 5% and top 5% of the distribution of ancestry-specific genetic scores and rs1050828 by genotype.\
The difference in measured HbA1c of individuals at the bottom 5% and top 5% of the distribution of an ancestry-specific additive GS composed of all 60 variants (GS-Total), and the equivalent calculation for an ancestry-specific GS composed of up to 20 erythrocytic variants (GS-E). Far right of the figure shows the mean HbA1c by genotype for chromosome X rs1050828. AA men, African American men; AA women, African American women; HbA1c, glycated hemoglobin; GS, genetic scores.](pmed.1002383.g005){#pmed.1002383.g005}

Erythrocytic variants alone explained around one-fifth to three-quarters of the total explained genetic variance in HbA1c ([S8 Table](#pmed.1002383.s009){ref-type="supplementary-material"}). The absolute differences in mean HbA1c from the bottom and top 5% of the GS-E distribution were similar to GS-Total, implying that genetically-induced differences in HbA1c may be largely driven by erythrocytic variants ([S9 Table](#pmed.1002383.s010){ref-type="supplementary-material"} and [S10 Table](#pmed.1002383.s011){ref-type="supplementary-material"}). In African Americans, this difference was largely driven by the C-to-T missense variant (G202A) in *G6PD*, rs1050828 on chromosome X. This variant alone explained 14.4% of variance in HbA1c (MESA; 9.6% in women; 19.9% in men). Men with the T allele had, on average, an absolute 0.81%-units (95% CI 0.66--0.96) lower HbA1c than those with the C allele. Homozygous TT women had, on average, an absolute 0.68%-units (95% CI 0.38--0.97) lower HbA1c compared to CC homozygous women. The effect size was similar after excluding those with anemia (Hb \< 12 g/dL in women and \< 13 g/dL in men, [S11 Table](#pmed.1002383.s012){ref-type="supplementary-material"}).

Fructosamine is another measure of serum protein glycation, which reflects glycemia over a 2--3 week window, but unlike HbA1c it is not influenced by RBC traits; therefore, we sought to explore the difference between fructosamine-inferred HbA1c and measured HbA1c (Methods, [S1 Analysis Plans](#pmed.1002383.s018){ref-type="supplementary-material"}) to test the hypothesis that the *G6PD* variant might be influencing HbA1c levels independently of ambient glycemia. Among African Americans, the T allele at rs1050828 was associated with measured HbA1c that was lower than fructosamine-predicted HbA1c (0.31%-units, 95% CI 0.25--0.37, *p* = 6.4 × 10^−19^). Among men with the C allele, measured HbA1c was similar to fructosamine-predicted HbA1c (residuals, 0.04%-units, 95% CI −0.04 to 0.12, *N* = 351). This suggested that only the T allele was associated with markedly lower HbA1c than expected from glycemic measurements ([S11 Table](#pmed.1002383.s012){ref-type="supplementary-material"}).

Public health implications of the *G6PD* variant on T2D screening {#sec025}
-----------------------------------------------------------------

Given the large effects of the *G6PD* G202A variant on HbA1c levels, we sought to investigate the impact this variant would have on diabetes detection if using HbA1c as a screening tool. To do this, we used publicly-available data from NHANES 2013--2014 \[[@pmed.1002383.ref034]\], a nationally representative sample of the US, to calculate the proportion of African Americans adults with T2D who would be missed by not accounting for rs1050828 when using a single HbA1c diagnostic threshold of 6.5%, assuming the observed effect size of rs1050828, allele frequency of 11%, and accounting for NHANES sampling design. In the NHANES sample of African Americans (*N* = 1,133), the mean age was 44.2 years (standard error 0.9), 55.2% were women, and mean HbA1c, excluding those with physician-diagnosed T2D, was 5.5%-units (standard error 0.02). 13.45% of African American adults aged ≥ 18 years had physician-diagnosed T2D with an additional 2.50% with undiagnosed T2D by HbA1c ≥ 6.5%. An additional estimated 2.17% (95% CI 1.88--2.46) with HbA1c \< 6.5% may be considered to have T2D if the effect of rs1050828 was accounted for by using genotype-specific diagnostic thresholds of 5.7% for T in men, 5.8% for TT, and 6.2% for TC in women. According to the 2014 United States Census Bureau, approximately 29.9 million adults identified themselves as African American \[[@pmed.1002383.ref036]\], suggesting that 0.65 (95% CI 0.55--0.74) million adults with T2D would remain undiagnosed when screened by a single HbA1c measurement if this genetic information were not taken into account ([S12 Table](#pmed.1002383.s013){ref-type="supplementary-material"}).

Discussion {#sec026}
==========

In a very large transancestry GWAS of HbA1c, we identified 42 novel and 18 known genetic variants associated with HbA1c, explaining 4%--14% of the trait variance. Genetic variants influencing HbA1c through erythrocytic pathways did not predict future T2D, and adjusting for their contribution to HbA1c led to a moderate misclassification of T2D by adjusted HbA1c. Notably, we detected strong ancestral differences in the contribution of genetic variants to HbA1c that substantially altered the performance of HbA1c as a diagnostic test for T2D in African Americans compared with Europeans and East Asians.

Our findings elucidate the contribution of common genetic variants to the genetic architecture of HbA1c and identify an important interface of modern human genetics with clinical and public health. In people of European and Asian ancestry, we found multiple genetic loci with small-to-modest effects, whereas, in African American ancestry, the genetic architecture was dominated by a single variant at *G6PD* (G202A). This variant was responsible for 0.81%-units HbA1c difference in men and 0.68%-units in homozygous TT women, corresponding to adjusted T2D diagnosis thresholds of 5.7 (95% CI 5.5--5.8) and 5.8 (95% CI 5.5--6.1), respectively. To meet the NGSP certification criteria, laboratory-reported HbA1c ought to be within 6% of the standard reference laboratory mean values (e.g., 6.5%-units ± 0.4%-units) for the majority of patient samples \[[@pmed.1002383.ref014]\]. The limits of acceptable analytic variability were exceeded by this *G6PD* variant. This may also have important implications for the management of diabetes, with carriers of the HbA1c-lowering *G6PD* allele requiring adjusted (lower) HbA1c treatment targets. Previous epidemiologic studies have shown that a 1%-unit increase in HbA1c in individuals without T2D was associated with a more than 2-fold increase in risk of future T2D and a 20%--50% increased risk of cardiovascular disease (CVD) \[[@pmed.1002383.ref037]\]. HbA1c ≥ 6.5% compared to those with HbA1c \< 5.7% had a higher risk of kidney disease and retinopathy \[[@pmed.1002383.ref038]\].

Only one other African-specific variant, rs11954649, located in the intron of *SOX30*, reached genome-wide significance in African Americans. However, this variant had a relatively small effect size (β = 0.12 per G allele) on HbA1c and was not classified as glycemic or erythrocytic. The variant was thus not included in the genetic scores and, unlike *G6PD*, the causal transcript and biological mechanism through which it influences HbA1c remains unclear. Future studies on larger sample sizes of ethnic minorities can focus on dissecting the genomic and biological implications of novel HbA1c-related variants.

When considering all ethnicities, both glycemic and erythrocytic variants influence measured HbA1c; yet, only glycemic variants were associated with increased T2D risk (5% per allele) over a decade-long follow-up period. For an equivalent HbA1c, individuals carrying more erythrocytic HbA1c-raising alleles, or fewer HbA1c-lowering alleles, had lower incident T2D risk (−5% per allele), implying that for the same HbA1c level those individuals with the greater number of erythrocytic HbA1c- raising alleles have artificially higher HbA1c values that do not reflect ambient glycemia. Thus, the influence of erythrocytic HbA1c variants may partly explain why some individuals with the same HbA1c may have different risks of future T2D. We note that the estimates of variance explained by genetic variants underlying HbA1c were comparable with those for FG in Europeans (4.8%) \[[@pmed.1002383.ref017]\].

Our results on the reclassification of prevalent T2D were consistent with previous reports indicating that a diagnostic cut-point at 6.5% for HbA1c classified fewer cases than FG ≥ 7 mmol/L \[[@pmed.1002383.ref039],[@pmed.1002383.ref040]\]. Adjusting for the contribution of erythrocytic variants correctly reclassified approximately 1 in 5 individuals with FG \< 7 mmol/L who were incorrectly diagnosed as having T2D (HbA1c ≥ 6.5%) to having HbA1c \< 6.5%, suggesting that a subset of these individuals may have artificially elevated HbA1c due to the contribution of the erythrocytic variants.

Though the specific *G6PD* variant we identified is monomorphic in Asian and European ancestry, other diverse *G6PD* variant alleles have reached polymorphic frequencies in malarial endemic regions around the world \[[@pmed.1002383.ref035]\]. G6PD deficiency is unlikely to be identified through routine screening for anemia in healthy individuals, and universal screening for G6PD deficiency is not currently recommended worldwide \[[@pmed.1002383.ref032],[@pmed.1002383.ref041]\]. Testing for G6PD deficiency is only performed on individuals before being prescribed specific drugs, such an antimalarial medications, or in patients with clinical presentation consistent with the disease; for instance, prolonged neonatal jaundice or hemolytic crisis following exposure to specific drugs, infections, or foods \[[@pmed.1002383.ref032]\]. Thus, asymptomatic individuals often remain unaware of their *G6PD* genotype status and screening for the *G6PD* genotype before using HbA1c to diagnose T2D may be warranted in populations or ethnic groups where G6PD deficiency is common. Similarly, a recent study identified a significant hemolytic risk in women heterozygous for the *G6PD* Mahidol variant when treated with primaquine who were not detected by current screening methods \[[@pmed.1002383.ref042]\]. Rarer hematologic conditions that reduce erythrocyte lifespan, e.g., hereditary hemolytic anemias, hereditary spherocytosis, and hemoglobinopathies have also been shown to lower HbA1c \[[@pmed.1002383.ref009],[@pmed.1002383.ref043]\], and should also be considered before using HbA1c in these patients. We recommend additional testing using direct glucose measurements (e.g., FG or oral glucose tolerance testing) or other erythrocyte-independent methods to diagnose T2D. This supports the use of a combination of HbA1c and FG to confirm T2D diagnosis in routine screening \[[@pmed.1002383.ref044]\]. Future studies could also explore *G6PD* effect modification by HbA1c assay type.

Further studies in large cohorts with HbA1c, glycemic, and erythrocytic traits are required to better determine the biological action of genetic variants that have yet to be classified. Similarly, future analyses conditional on RBC distribution width or reticulocyte count will help to better understand the effects of erythrocytic HbA1c-associated variants, should such data become available. The relatively small sample size for Asian and African ancestry cohorts limited the discovery of ancestry-specific genetic variants, beyond the African-specific *G6PD* variant, and could explain why GS-G was associated with higher incident T2D in European, but not other, ancestries. This underscores the need to extend such studies to non-European populations, particularly those with a high prevalence of some hemoglobinopathies or iron deficiency anemias. Epidemiologic studies have reported higher mean HbA1c in African Americans compared to European ancestry individuals in the US \[[@pmed.1002383.ref045],[@pmed.1002383.ref046]\]. While our genetic findings could not determine whether this difference was completely attributable to relative hyperglycemia, accounting for the effect of the *G6PD* variant that lowers HbA1c only in African Americans would further widen this disparity.

In conclusion, HbA1c remains an appropriate diagnostic test for the majority of people of diverse genetic backgrounds, having lower intraindividual variability compared to FG with the ability to capture chronic hyperglycemia, and robust associations with T2D-related complications \[[@pmed.1002383.ref037]\]. Nevertheless, nonglycemic lowering of measured HbA1c for 1 in 10 African American men who carry this *G6PD* variant, and 1 in a 100 African American women homozygous for this variant, could amount to 0.65 (95% CI 0.56--0.74) million African American adults in the US with a missed T2D diagnosis using HbA1c as a screening test. We therefore recommend investigation of the possible benefits of screening for the *G6PD* genotype along with using HbA1c to diagnose T2D in populations of African ancestry or groups where G6PD deficiency is common, and screening with direct glucose measurements, or genetically-informed HbA1c diagnostic thresholds in people with G6PD deficiency. This work supports a role for a precision medicine application to reduce race-ethnic health disparities using HbA1c genetics to improve T2D diagnosis and prediction and to inform screening strategies for T2D across the African continent where the prevalence of the *G6PD* variant can reach 20%.
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